YD Bio Ltd SEC Filings

Welcome to our dedicated page for YD Bio SEC filings (Ticker: YDESW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

This page provides access to YD Bio Limited (YDESW) SEC filings, including reports that describe its activities as a biopharmaceutical company focused on blood-based cancer detection, stem cell-based therapeutics, exosome-based therapeutics, and the supply of clinical testing drugs for pharmaceutical companies. As a foreign private issuer, YD Bio Limited files annual reports on Form 20-F and current reports on Form 6-K with the U.S. Securities and Exchange Commission.

In its Form 6-K dated September 19, 2025, the company discloses a change in its independent registered public accounting firm, the termination of the engagement of CBIZ CPAs P.C., and the appointment of ARK Pro CPA & Co for the fiscal year ending December 31, 2025. The filing explains that prior audit reports from CBIZ CPAs included an explanatory paragraph about substantial doubt regarding the company’s ability to continue as a going concern, while also noting that there were no disagreements on accounting principles, financial statement disclosure, or auditing scope or procedure that required reference in the audit reports.

Through this filings page, users can review such disclosures, along with other documents like annual Form 20-F reports and additional Form 6-K submissions, to understand YD Bio Limited’s financial reporting, auditor relationships, and governance-related information. The platform offers AI-powered summaries that highlight key points from lengthy filings, helping readers interpret going concern language, auditor changes, and other technical disclosures without needing to read every page in detail.

In addition to narrative reports, this page also surfaces relevant SEC documents that may include information on the company’s biopharmaceutical focus, risk factors, and other regulatory content tied to the YDESW symbol, giving investors and researchers a structured way to review YD Bio Limited’s public reporting history.